A Single Agent Phase II Study of Romidepsin (Depsipeptide, FK228) in the Treatment of Cutaneous T-cell Lymphoma (CTCL)
A phase 2 trial of Romidepsin in Cutaneous T-cell lymphoma, run by Celgene, completed.
Overview
A Single Agent Phase II Study of Romidepsin (Depsipeptide, FK228) in the Treatment of Cutaneous T-cell Lymphoma (CTCL) is a phase 2 interventional study registered as NCT00106431 by Celgene, with 102 participants recorded, started 2005-01-01 and reaching its primary completion in 2008-06-01. Interventions recorded: romidepsin (depsipeptide, FK228). Conditions recorded: Cutaneous T-cell Lymphoma.
Linked to the drug Romidepsin because the registry names it among its interventions and Cutaneous T-cell lymphoma among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialA Study of Navlimetostat (BMS-986504) in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion (MountainTAP-9)
Shares Bristol Myers Squibb and the tag pipeline.
- TrialLong-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
Shares Bristol Myers Squibb and the tag pipeline.
- TrialAn Efficacy and Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy in Chinese Participants With Acute Myeloid Leukemia in Complete Remission
Shares Bristol Myers Squibb and the tag pipeline.
- TrialPUVA Maintenance Therapy in Mycosis Fungoides
Shares Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome) and the tag pipeline.
- TrialA Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)
Shares Bristol Myers Squibb and the tag pipeline.
- TrialRandomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL
Shares Romidepsin and the tag pipeline.
- TrialFLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides)
Shares Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome) and the tag pipeline.
- TrialA Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors
Shares Bristol Myers Squibb and the tag pipeline.